[Patient acceptance of NovoLet--an integrated insulin dosage system for repeated use. A multicenter study]

A total of 394 insulin treated diabetic patients from 22 diabetic outpatient clinics all over Denmark were recruited to participate in an open, uncontrolled study of 12 weeks duration. The aim was to test the acceptability of a new pen device, NovoLet, a disposable, multidose pen containing Protaphan 150 International Units. All patients were receiving NPH insulin (Insulatard or Protaphan +/- soluble insulin) prior to inclusion. The insulin regimen otherwise remained unchanged during the study period and 372 patients completed the study. No changes in metabolic control as judged by HbA1c% and frequency of severe hypoglycemic episodes were observed. The total daily insulin dose remained unchanged. Of the 372 patients, 98 were on Insulatard on inclusion in the study. No changes in metabolic control or insulin dose were observed. Patient acceptance of NovoLet was good, 62% would prefer to continue to use it.